Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Valby, Denmark, 21 May 2019 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.
|1.||Details of the person discharging managerial responsibilities / person closely associated|
|2.||Reason for the notification|
|a)||Position/status||Executive Vice President, Product Development & Supply|
|b)||Initial notification/Amendment||Initial notification|
|3.|| Details of the issuer, emission allowance market participant,|
auction platform, auctioneer or auction monitor
|a)||Name||H. Lundbeck A/S|
|4||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a)|| Description of the financial|
instrument, type of instrument
|b)||Nature of the transaction||Sale of Shares|
|c)||Price(s) and volume(s)||Price(s)||Volume(s)|
|d)|| Aggregated information|
- Aggregated volume
|e)||Date of the transaction||2019-05-21|
|f)||Place of the transaction||NASDAQ Copenhagen XCSE|
Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.
Closely associated persons/entities means inter alia:
- spouse or cohabitant
- dependent children
- legal entities in which the executive has a controlling influence.
Palle Holm Olesen
Vice President, Investor Relations
+45 30 83 24 26
Senior Director, Corporate Communication
+45 36 43 40 00
About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18,1 billion in 2018 (EUR 2,4 billion; USD 2,8 billion).
Upcoming Life Sciences Events
- September 2019
- Munich: The Biotech & Pharma Summit: Drug Delivery & Formulation
- Brussels: The Pharma Forecasting Course
- Bangkok: Bio Investment Asia 2019